Company Profile
Assertio Stock Price, News & Analysis
- Ticker:
- ASRT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
23.50 USD (+0.13%)
Close
Last updated: June 15, 2026
152M USD
Market cap
Why the stock is moving
Current closing-price context is not available for ASRT.
Company overview
Business overview
Assertio is a specialty pharmaceutical company with a portfolio of neurology, pain, and related products. The story is largely about managing a concentrated commercial base while expanding selectively.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Assertio sits in specialty biopharma.
Business Model Characteristics
The business depends on product revenue, portfolio management, and the ability to stabilize and grow its commercial assets.
Position Within the Biotechnology Landscape
Assertio is a specialty-pharma turnaround name with a story shaped by product mix and execution.
Future catalysts
Assertio’s catalysts are its branded pain and neurology portfolio, including Sympazan and Indocin, plus any capital-allocation or portfolio-optimization update. The market will care more about cash generation and simplification than about big pipeline headlines.
Recent news
- 01
Assertio Announces Leadership Transition
Source: Assertio
- 02
- 03
- 04
- 05
Assertio Reports Second Quarter 2025 Financial Results
Source: Assertio
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Assertio (ASRT)?
Assertio (ASRT) most recently closed at 23.50 USD, a +0.13% move versus the previous session.
What is the market cap of Assertio (ASRT)?
Assertio currently has a market capitalization of 152M USD on BioPharmSignal.
What does Assertio do?
Assertio is a specialty pharmaceutical company with a portfolio of neurology, pain, and related products. The story is largely about managing a concentrated commercial base while expanding selectively.
On which exchange is ASRT stock listed?
Assertio (ASRT) is associated with NASDAQ, United States, Biopharma.
What is Assertio?
Assertio’s catalysts are its branded pain and neurology portfolio, including Sympazan and Indocin, plus any capital-allocation or portfolio-optimization update.
Which conditions is Assertio targeting with Assertio?
Assertio is associated with neurology based on its company overview and current catalyst commentary.
How does Assertio describe recent progress with Assertio?
Assertio’s catalysts are its branded pain and neurology portfolio, including Sympazan and Indocin, plus any capital-allocation or portfolio-optimization update.
What is Sympazan?
Assertio’s catalysts are its branded pain and neurology portfolio, including Sympazan and Indocin, plus any capital-allocation or portfolio-optimization update.